{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:16Z","timestamp":1793075596847,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100497","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:49:43Z","timestamp":1790380183000},"page":"100497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementation"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9246-9441","authenticated-orcid":false,"given":"Iolanda","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Birceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-4500","authenticated-orcid":false,"given":"Laura","family":"Mazilu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Manolache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100497_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jlb.2026.100497_bib2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jlb.2026.100497_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jlb.2026.100497_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jlb.2026.100497_bib5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100497_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100497_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100497_bib8","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jlb.2026.100497_bib9","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100497_bib10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100497_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jtho.2024.09.1443","article-title":"Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis","volume":"20","author":"Marinelli","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-022-00262-y","article-title":"A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy","volume":"6","author":"Rajakumar","year":"2022","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib14","article-title":"Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jlb.2026.100497_bib15","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-24-142","article-title":"Potential predictors of the pathologic response after neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer: a narrative review","volume":"13","author":"Kaira","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15050631","article-title":"Current biomarkers in non-small cell lung cancer: the molecular pathologist's perspective","volume":"15","author":"Steinestel","year":"2025","journal-title":"Diagnostics"},{"key":"10.1016\/j.jlb.2026.100497_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-022-01505-z","article-title":"Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41419-023-05757-5","article-title":"Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jlb.2026.100497_bib19","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jlb.2026.100497_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jlb.2026.100497_bib21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/gcc.22032","article-title":"Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer","volume":"52","author":"Zandberga","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib22","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41576-023-00611-y","article-title":"microRNAs in action: biogenesis, function and regulation","volume":"24","author":"Shang","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jlb.2026.100497_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2023.2288741","article-title":"Recent progress in miRNA biogenesis and decay","volume":"21","author":"Bofill-De Ros","year":"2024","journal-title":"RNA Biol"},{"key":"10.1016\/j.jlb.2026.100497_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib25","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/jcm8101661","article-title":"Circulating miRNAs as diagnostic and prognostic biomarkers in common solid tumors: focus on lung, breast, prostate cancers, and osteosarcoma","volume":"8","author":"Bottani","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jlb.2026.100497_bib26","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jlb.2026.100497_bib27","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jlb.2026.100497_bib28","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1038\/ncomms3980","article-title":"Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs","volume":"4","author":"Villarroya-Beltri","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2026.100497_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12318","article-title":"The glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells","volume":"12","author":"Ko","year":"2023","journal-title":"J Extracell Vesicles"},{"key":"10.1016\/j.jlb.2026.100497_bib30","doi-asserted-by":"crossref","DOI":"10.11613\/BM.2024.020501","article-title":"Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement","volume":"34","author":"Zendjabil","year":"2024","journal-title":"Biochem Med"},{"key":"10.1016\/j.jlb.2026.100497_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227648","article-title":"Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples","volume":"15","author":"Matias-Garcia","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jlb.2026.100497_bib32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1373\/clinchem.2010.157198","article-title":"Analysis of circulating MicroRNA: preanalytical and analytical challenges","volume":"57","author":"McDonald","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.jlb.2026.100497_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1515\/cclm-2023-0131","article-title":"Evidence-based procedures to improve the reliability of circulating miRNA biomarker assays","volume":"62","author":"Greytak","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jlb.2026.100497_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10408363.2022.2128030","article-title":"Development of circulating microRNA-based biomarkers for medical decision-making: a friendly reminder of what should NOT be done","volume":"60","author":"Lakkisto","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/nmeth.3014","article-title":"Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study","volume":"11","author":"Mestdagh","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.jlb.2026.100497_bib36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.celrep.2018.10.014","article-title":"Large differences in small RNA composition between human biofluids","volume":"25","author":"Godoy","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12896-016-0292-7","article-title":"A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer","volume":"16","author":"Campomenosi","year":"2016","journal-title":"BMC Biotechnol"},{"key":"10.1016\/j.jlb.2026.100497_bib38","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"10.1016\/j.jlb.2026.100497_bib39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1373\/clinchem.2015.239459","article-title":"Data normalization strategies for MicroRNA quantification","volume":"61","author":"Schwarzenbach","year":"2015","journal-title":"Clin Chem"},{"key":"10.1016\/j.jlb.2026.100497_bib40","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41598-019-38505-x","article-title":"Normalization strategies differently affect circulating miRNA profile associated with the training status","volume":"9","author":"Faraldi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib44","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s41416-024-02831-3","article-title":"Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)","volume":"131","author":"Abdipourbozorgbaghi","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib45","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/1940-6207.CAPR-11-0370","article-title":"Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies","volume":"5","author":"Pritchard","year":"2012","journal-title":"Cancer Prev Res Phila Pa"},{"key":"10.1016\/j.jlb.2026.100497_bib46","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Br Med J"},{"key":"10.1016\/j.jlb.2026.100497_bib48","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1515\/cclm-2024-0531","article-title":"Navigating the path of reproducibility in microRNA-based biomarker research with ring trials","volume":"62","author":"Sopi\u0107","year":"2024","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jlb.2026.100497_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1373\/clinchem.2015.251942","article-title":"Optimization and standardization of circulating MicroRNA detection for clinical application: the miR-Test case","volume":"62","author":"Marzi","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jlb.2026.100497_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv063","article-title":"miR-Test: a blood test for lung cancer early detection","volume":"107","author":"Montani","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jlb.2026.100497_bib43","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/ijms22031176","article-title":"Measurements methods for the development of MicroRNA-Based tests for cancer diagnosis","volume":"22","author":"Precazzini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib50","article-title":"MicroRNA-21 identified as predictor of cancer outcome: a meta-analysis","volume":"9","author":"Zhu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jlb.2026.100497_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.gene.2013.09.038","article-title":"Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis","volume":"533","author":"Wang","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.jlb.2026.100497_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09674845.2019.1592915","article-title":"Clinical significance of serum miR-25 in non-small-cell lung cancer","volume":"76","author":"Li","year":"2019","journal-title":"Br J Biomed Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1159\/000488823","article-title":"Clinical significance of miR-210 and its prospective signaling pathways in non-small cell lung cancer: evidence from gene expression omnibus and the cancer genome atlas data mining with 2763 samples and validation via real-time quantitative PCR","volume":"46","author":"He","year":"2018","journal-title":"Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol"},{"key":"10.1016\/j.jlb.2026.100497_bib60","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejca.2012.09.031","article-title":"High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer","volume":"49","author":"Yang","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib63","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","article-title":"Reduced expression of the let-7 MicroRNAs in human lung cancers in association with shortened postoperative survival","volume":"64","author":"Takamizawa","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib64","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1183\/09031936.00029610","article-title":"Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival","volume":"37","author":"Silva","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jlb.2026.100497_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101899","article-title":"miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma","volume":"9","author":"Tejero","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jlb.2026.100497_bib68","first-page":"2597","article-title":"The diagnostic and prognostic role of circulating miR-141 expression in non-small-cell lung cancer patients","volume":"11","author":"Zhao","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jlb.2026.100497_bib71","doi-asserted-by":"crossref","DOI":"10.21037\/jtd.2017.09.01","article-title":"Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer","volume":"9","author":"Zhao","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jlb.2026.100497_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1055-9965.EPI-18-0569","article-title":"Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy","volume":"28","author":"Yuwen","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jlb.2026.100497_bib74","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.2147\/IJN.S221383","article-title":"Exosomal transfer of cisplatin-induced miR-425-3p confers cisplatin resistance in NSCLC through activating autophagy","volume":"14","author":"Ma","year":"2019","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.jlb.2026.100497_bib75","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1541-7786.MCR-10-0052","article-title":"Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer","volume":"8","author":"Ceppi","year":"2010","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.jlb.2026.100497_bib56","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/jpm12081227","article-title":"The role of the selected miRNAs as diagnostic, predictive and prognostic markers in non-small-cell lung cancer","volume":"12","author":"Szczyrek","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.jlb.2026.100497_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102435","article-title":"Large-scale profiling of extracellular vesicles identified miR-625-5p as a novel biomarker of immunotherapy response in advanced non-small-cell lung cancer patients","volume":"14","author":"Pantano","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jlb.2026.100497_bib49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3892\/br.2016.747","article-title":"Emerging role of microRNA-21 in cancer","volume":"5","author":"Feng","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12253-015-9979-7","article-title":"Up-Regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer","volume":"22","author":"Tian","year":"2016","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jlb.2026.100497_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/carcin\/bgw110","article-title":"MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP\/TAZ oncogenic activity in lung cancer","volume":"38","author":"Lo Sardo","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jlb.2026.100497_bib55","first-page":"5251","article-title":"Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer","volume":"23","author":"Zhang","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/0300060513497560","article-title":"Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer","volume":"41","author":"Li","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jlb.2026.100497_bib59","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1186\/s12885-019-6297-6","article-title":"The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis","volume":"19","author":"Shao","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-022-02244-1","article-title":"Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p\/PD-L1 pathway","volume":"41","author":"Li","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126543","article-title":"MicroRNA-155 coordinates the immunological landscape within Murine melanoma and correlates with immunity in human cancers","volume":"4","author":"Ekiz","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jlb.2026.100497_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/life14121608","article-title":"Exosome-derived miRNAs in liquid biopsy for lung cancer","volume":"14","author":"Mart\u00ednez-Espinosa","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.jlb.2026.100497_bib66","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1186\/s40169-019-0240-y","article-title":"Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer","volume":"8","author":"Chirshev","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jlb.2026.100497_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.965231","article-title":"The role of miR-200 family in the regulation of hallmarks of cancer","volume":"12","author":"Klicka","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/srep12464","article-title":"A novel serum 4-microRNA signature for lung cancer detection","volume":"5","author":"Nadal","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib72","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.14527","article-title":"Treatments and outcomes after platinum-based chemotherapy and Anti-PD-(L)1 in NSCLC","volume":"8","author":"Velcheti","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jlb.2026.100497_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-61779-427-8_18","article-title":"miRNA expression profiling: from reference genes to global mean normalization","volume":"822","author":"D'haene","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jlb.2026.100497_bib77","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib78","article-title":"Brief report: a blood-based MicroRNA complementary diagnostic predicts immunotherapy efficacy in advanced-stage NSCLC with high programmed death-ligand 1 expression","volume":"3","author":"Rajakumar","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib79","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.ygeno.2019.11.019","article-title":"Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer","volume":"112","author":"Fan","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.jlb.2026.100497_bib80","doi-asserted-by":"crossref","DOI":"10.21037\/tcr-20-2815","article-title":"Exosomal microRNAs in non-small cell lung cancer","volume":"10","author":"Dur\u00e9ndez-S\u00e1ez","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib82","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.2018.9","article-title":"PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC","volume":"118","author":"Del Re","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib83","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1038\/s41598-021-87575-3","article-title":"Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer","volume":"11","author":"Shimada","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100497_bib84","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100497_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12967-019-2101-2","article-title":"Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients","volume":"17","author":"Li","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.jlb.2026.100497_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1489977","article-title":"Biomarkers for immunotherapy resistance in non-small cell lung cancer","volume":"14","author":"Rother","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jlb.2026.100497_bib88","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib89","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2026.100497_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7455","article-title":"Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells","volume":"7","author":"Guo","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.jlb.2026.100497_bib91","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2015.10","article-title":"The clinical relevance of the miR-197\/CKS1B\/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer","volume":"23","author":"Fujita","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jlb.2026.100497_bib92","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib93","doi-asserted-by":"crossref","first-page":"532","DOI":"10.21037\/tlcr.2020.04.01","article-title":"ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib","volume":"9","author":"Romero","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib94","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1038\/s41467-025-63696-5","article-title":"Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy","volume":"16","author":"Schmid","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2026.100497_bib95","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1515\/jtim-2025-0052","article-title":"A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"13","author":"Zhai","year":"2025","journal-title":"J Transl Intern Med"},{"key":"10.1016\/j.jlb.2026.100497_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jlb.2026.100497_bib97","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100497_bib98","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100497_bib99","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: a review","volume":"126","author":"Cisneros-Villanueva","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jlb.2026.100497_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262412035","article-title":"Blood-based miRNA panels for timely detection of non-small-cell lung cancer: from biomarker discovery to clinical translation","volume":"26","author":"Zedan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib108","first-page":"94","article-title":"The impact of hemolysis on cell-free microRNA biomarkers","volume":"4","author":"Kirschner","year":"2013","journal-title":"Front Genet"},{"key":"10.1016\/j.jlb.2026.100497_bib109","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s42003-020-0863-y","article-title":"A miRNA-based diagnostic model predicts resectable lung cancer in humans with high accuracy","volume":"3","author":"Asakura","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.jlb.2026.100497_bib110","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.3390\/cells10061520","article-title":"Dynamic evaluation of circulating miRNA profile in EGFR-mutated NSCLC patients treated with EGFR-TKIs","volume":"10","author":"Leonetti","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jlb.2026.100497_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70463","article-title":"Lexicon for clonal hematopoiesis in liquid biopsy","volume":"19","author":"Tell","year":"2026","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jlb.2026.100497_bib100","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1078-0432.CCR-24-3335","article-title":"Characterization of plasma cell-free DNA variants as of tumor or clonal hematopoiesis origin in 16,812 advanced cancer patients","volume":"31","author":"Magee","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jlb.2026.100497_bib102","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.jlb.2026.100497_bib103","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-026-04280-9","article-title":"MicroRNA-regulated signaling and tumor microenvironment modulation in lung cancer: mechanistic insights and translational opportunities","volume":"26","author":"Shrestha","year":"2026","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jlb.2026.100497_bib104","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00432-022-04034-w","article-title":"Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach","volume":"149","author":"Englmeier","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/cells9020276","article-title":"miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis","volume":"9","author":"Condrat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jlb.2026.100497_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1152470","article-title":"Enhancing clinical potential of liquid biopsy through a multi-omic approach: a systematic review","volume":"14","author":"Di Sario","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.jlb.2026.100497_bib111","doi-asserted-by":"crossref","first-page":"16674","DOI":"10.18632\/oncotarget.4322","article-title":"Longitudinal study on circulating miRNAs in patients after lung cancer resection","volume":"6","author":"Leidinger","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jlb.2026.100497_bib112","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41388-024-03076-3","article-title":"MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances","volume":"43","author":"Metcalf","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.jlb.2026.100497_bib113","first-page":"1","article-title":"MicroRNAs in oncology: a translational perspective in the era of AI","author":"Jurj","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100497_bib114","doi-asserted-by":"crossref","first-page":"13048","DOI":"10.18632\/oncotarget.14369","article-title":"Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer","volume":"8","author":"Liu","year":"2016","journal-title":"Oncotarget"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:00:56Z","timestamp":1793073656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":114,"alternative-id":["S2950195426000433"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100497","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating MicroRNAs in non-small cell lung cancer: Clinical potential, analytic pitfalls, and barriers to implementation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100497"}}